| 
						FDA warns against use of 
						homeopathic teething products 
   Send a link to a friend 
		[January 28, 2017] 
		(Reuters) - The U.S. Food and Drug Administration on Friday 
		warned consumers against using certain homeopathic teething products, 
		saying it has found high amounts of a toxic substance in some of them 
		and they pose a potential risk to infants and children. | 
        
            | 
			
			 Laboratory analysis found amounts of belladonna, a toxic substance, 
			that sometimes far exceeded the amount claimed on the label of these 
			teething tablets, the FDA said. 
 Homeopathic teething tablets are used to provide temporary relief of 
			teething symptoms in children.
 
 Inconsistent levels of belladonna can cause seizures, excessive 
			sleepiness, muscle weakness and skin flushing in children.
 
 The FDA asked Los Angeles-based Standard Homeopathic Co, the 
			manufacturer of Hyland's teething products, to recall the products 
			from the market, but said the company did not agree to the recall.
 
			
			 
			Hyland's said it declined to recall the teething products because it 
			had discontinued them in October after the FDA in September 
			re-opened a 2010 investigation into their safety. That followed 
			another report of a child who had seizure after using the teething 
			tablets.
 At this time "we don't see any additional action to be necessary," 
			Hyland's spokeswoman Mary Borneman said.
 
 The FDA had found over 400 side effects reports, including 10 deaths 
			since 2010, according to several reports at that time.
 
			
            [to top of second column] | 
 
			In November, Raritan Pharmaceuticals Inc recalled three 
			belladonna-containing homeopathic products, two of which were 
			marketed by CVS Health Corp.
 In 2010, Standard Homeopathic voluntarily recalled Hyland's teething 
			tablets from the market to address manufacturing issues. (http://bit.ly/2jnvJsO)
 
 (Reporting by Divya Grover in Bengaluru; Editing by Shounak Dasgupta 
			and Leslie Adler)
 
			[© 2017 Thomson Reuters. All rights 
				reserved.] Copyright 2017 Reuters. All rights reserved. This material may not be published, 
			broadcast, rewritten or redistributed. 
			
			
			 |